StockData
Anixa Biosciences Inc logo

Anixa Biosciences Inc (ANIX) stock

ANIXNasdaqPharmaceutical PreparationsFiscal year ends October 31
Financials through Q3 FY2026, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 9, 2026Score 6/30
$2.71+0.04 (+1.50%)

Close on Nov 18, 2026Market cap $94.21MP/E –Yield –

Anixa Biosciences operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Anixa Biosciences's operating income for the twelve months ending Jul 31, 2026 was -$10.98M. For fiscal 2025 it was -$11.70M. The highest annual figure on record is -$944.76K in fiscal 2015.

Annual operating income

PeriodPeriod endValueChange
FY2025Oct 31, 2025-$11.70M–
FY2024Oct 31, 2024-$13.83M–
FY2023Oct 31, 2023-$11.01M–
FY2022Oct 31, 2022-$13.88M–
FY2021Oct 31, 2021-$13.14M–
FY2020Oct 31, 2020-$9.98M–
FY2019Oct 31, 2019-$11.89M–
FY2018Oct 31, 2018-$14.29M–
FY2017Oct 31, 2017-$6.08M–
FY2016Oct 31, 2016-$4.51M–
FY2015Oct 31, 2015-$944.76K–
FY2014Oct 31, 2014-$5.04M–
FY2013Oct 31, 2013-$7.92M–
FY2012Oct 31, 2012-$4.13M–
FY2011Oct 31, 2011-$5.03M–
FY2010Oct 31, 2010-$5.25M–

Quarterly operating income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ2 2026Jul 31, 2026-$2.74M–
Q2 FY2026CQ1 2026Apr 30, 2026-$2.65M–
Q1 FY2026CQ4 2025Jan 31, 2026-$2.72M–
Q4 FY2025CQ3 2025Oct 31, 2025-$2.88M–
Q3 FY2025CQ2 2025Jul 31, 2025-$2.44M–
Q2 FY2025CQ1 2025Apr 30, 2025-$3.00M–
Q1 FY2025CQ4 2024Jan 31, 2025-$3.39M–
Q4 FY2024CQ3 2024Oct 31, 2024-$3.16M–
Q3 FY2024CQ2 2024Jul 31, 2024-$3.59M–
Q2 FY2024CQ1 2024Apr 30, 2024-$3.47M–
Q1 FY2024CQ4 2023Jan 31, 2024-$3.61M–
Q4 FY2023CQ3 2023Oct 31, 2023-$3.05M–
Q3 FY2023CQ2 2023Jul 31, 2023-$2.84M–
Q2 FY2023CQ1 2023Apr 30, 2023-$2.56M–
Q1 FY2023CQ4 2022Jan 31, 2023-$2.56M–
Q4 FY2022CQ3 2022Oct 31, 2022-$3.61M–
Q3 FY2022CQ2 2022Jul 31, 2022-$2.80M–
Q2 FY2022CQ1 2022Apr 30, 2022-$3.59M–
Q1 FY2022CQ4 2021Jan 31, 2022-$3.88M–
Q4 FY2021CQ3 2021Oct 31, 2021-$4.08M–
Q3 FY2021CQ2 2021Jul 31, 2021-$4.39M–
Q2 FY2021CQ1 2021Apr 30, 2021-$2.44M–
Q1 FY2021CQ4 2020Jan 31, 2021-$2.23M–
Q4 FY2020CQ3 2020Oct 31, 2020-$2.24M–
Q3 FY2020CQ2 2020Jul 31, 2020-$2.44M–
Q2 FY2020CQ1 2020Apr 30, 2020-$2.67M–
Q1 FY2020CQ4 2019Jan 31, 2020-$2.63M–
Q4 FY2019CQ3 2019Oct 31, 2019-$2.13M–
Q3 FY2019CQ2 2019Jul 31, 2019-$2.18M–
Q2 FY2019CQ1 2019Apr 30, 2019-$2.59M–
Q1 FY2019CQ4 2018Jan 31, 2019-$4.98M–
Q4 FY2018CQ3 2018Oct 31, 2018-$5.41M–
Q3 FY2018CQ2 2018Jul 31, 2018-$5.61M–
Q2 FY2018CQ1 2018Apr 30, 2018-$1.40M–
Q1 FY2018CQ4 2017Jan 31, 2018-$1.87M–
Q4 FY2017CQ3 2017Oct 31, 2017-$1.74M–
Q3 FY2017CQ2 2017Jul 31, 2017-$1.73M–
Q2 FY2017CQ1 2017Apr 30, 2017-$1.21M–
Q1 FY2017CQ4 2016Jan 31, 2017-$1.39M–
Q4 FY2016CQ3 2016Oct 31, 2016-$913.30K–

More Anixa Biosciences figures

See a number that looks wrong?